Tenaya CEO Faraz Ali to Showcase Gene Therapies at Two Major Conferences
Tenaya Therapeutics' CEO, Faraz Ali, will participate in two significant conferences this October, showcasing the company's innovative gene therapies for cardiac diseases. The Chardan Annual Genetic Medicines Conference and the Cell & Gene Meeting on the Mesa will feature Ali in panel discussions, highlighting Tenaya's promising pipeline.
At the Chardan conference on October 21, Ali will delve into 'In Vivo Gene Therapies for Genetic Cardiac Diseases'. Tenaya's pipeline, including TN-201 for MYBPC3-associated HCM and TN-401 for PKP2-associated ARVC, will be in the spotlight. A live webcast and archived replay will be available on Tenaya's website.
Earlier in the month, on October 6, Ali will present at the Cell & Gene Meeting on the Mesa. He will participate in a panel discussing 'Future Horizons' and give a company presentation. Tenaya's clinical-stage small molecule HDAC6 inhibitor, TN-301, for heart failure treatment, will also be featured. Ali's participation in the JP Morgan Healthcare Conference and Evercore ISI HealthCONX in October further underscores Tenaya's commitment to advancing its therapies.
Faraz Ali's appearances at these conferences underscore Tenaya Therapeutics' leadership in gene therapies for heart disease. The company's pipeline, including TN-201, TN-401, and TN-301, holds promise for potentially curative treatments. With Ali's insights and Tenaya's innovative approach, the future of cardiac therapies looks increasingly hopeful.
Read also:
- U.S. CBP's Operation Plaza Spike Boosts Fentanyl Seizures Along Arizona-Mexico Border
- Regensburg Court Sentences Pizza Delivery Owner for Illegal Employment, Tax Evasion
- Tesla's EV Market Share Plummets in Europe, US Competition Intensifies
- Catastrophe at a U.S. Steel facility in Pennsylvania results in the loss of two lives. crucial details unveiled
